NEW YORK, Dec. 15 (GenomeWeb News) - Invitrogen and Genoway will co-market RNAi-related services, the companies said today.
Under the agreement, Invitrogen will combine its expertise in RNAi research technologies with Genoway's portfolio of transgenesis technologies and RNAi in vivo experience to create a new services platform. The platform will allow RNAi vector design through the creation of RNAi transgenic rodent models.
Both companies will share revenues, Genoway said.
Additional details were not disclosed.